Skip to main content
OliX Pharmaceuticals, Inc. logo

OliX Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · 226950 ISIN · KR7226950004 KO Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2023-03-09 Regulatory Filings
Country KR South Korea
Listing KO 226950

About OliX Pharmaceuticals, Inc.

https://olixpharma.com

OliX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the development of therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric siRNA (asiRNA) platform to create treatments that selectively silence disease-causing genes. Its research and development efforts are focused on building a robust pipeline of drug candidates targeting a variety of illnesses with high unmet medical needs. The pipeline has a particular emphasis on ophthalmic and dermal disorders, with key programs addressing conditions such as hypertrophic scars, age-related macular degeneration (AMD), and other fibrotic and ocular diseases.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(안드로겐성 탈모가 있는 건강한 남성을 대상으로 OLX72021의 안전성, 내약성 및 약동학적 특성을 평가하기 위한 다기관, 무작위배정, 이중눈가림, 단일용량상승, 위약대조, 제1상 임상시험 계획 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (OliX) regarding the approval of a Phase 1 clinical trial for a drug candidate (OLX72021). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) filed with the Korea Exchange (KRX). Since this is a specific regulatory announcement regarding clinical trial status and does not fit into categories like financial reports, dividends, or M&A, it is classified as a general regulatory filing.
2023-03-09 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details changes in share ownership by major shareholders and their special related parties, including specific disclosures about collateral contracts. This falls under the category of Major Shareholding Notification.
2023-03-06 Korean
투자판단관련주요경영사항(GalNAc-asiRNA 기술을 이용한 Option 1종 행사)
M&A Activity Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KRX) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details a specific business transaction involving the exercise of an option under a previously signed license agreement with Jiangsu Hansoh Pharmaceuticals. Since this is a specific corporate announcement regarding a material business contract and does not fit into categories like M&A (which usually implies a merger or acquisition of a company) or other specific categories, it is best classified as a general Regulatory Filing (RNS).
2023-02-27 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company 'OliX'. It outlines the date, location, agenda items (such as financial statement approval, director appointments, and remuneration limits), and voting procedures. This document is a standard proxy solicitation material sent to shareholders to inform them of the upcoming meeting and the matters to be voted upon, which fits the definition of a Proxy Solicitation & Information Statement.
2023-02-24 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the granting of stock options (주식매수선택권 부여). It details the board resolution, the purpose of the grant, the exercise price, and the list of recipients. This type of disclosure is a standard regulatory requirement for listed companies in Korea to report changes in capital structure or equity-based compensation. Since it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for new shares), and it is a formal regulatory announcement, it is classified as a Regulatory Filing (RNS).
2023-02-24 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically a '정정신고' (Amendment Report). It details changes to previously granted stock options, including cancellations and adjustments to the total number of options. In the context of financial filings, reports regarding the issuance or modification of stock options (equity-based compensation) are classified under 'Regulatory Filings' (RNS) as they represent specific corporate actions that do not fit into the other specialized categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for capital changes).
2023-02-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.